The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19
Open accessAbstract
Background & Aims Liver enzyme abnormalities are common in patients with coronavirus disease 2019 (COVID-19). Whether or not severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can lead to liver damage per se remains unknown. Herein, we reported the clinical characteristics and liver pathological manifestations of COVID-19 patients with liver enzyme abnormalities. Methods We analyzed 156 patients diagnosed with COVID-19 from 2 designated centers in China and compared clinical features between patients with or without elevated aminotransferases. Postmortem liver biopsies were obtained from 2 cases who had elevated aminotransferases. We investigated the patterns of liver impairment by electron microscopy, immunohistochemistry, TUNEL assay and pathological studies. Results Sixty-four out of 156 (41.0%) patients with COVID-19 had elevated aminotransferases. The median levels of alanine aminotransferase were 50 U/L vs. 19 U/L, respectively, aspartate aminotransferase were 45.5 U/L vs. 24 U/L, respectively in abnormal and normal aminotransferase groups. Liver enzyme abnormalities were associated with disease severity, as well as a series of laboratory tests including higher alveolar-arterial oxygen partial pressure difference, higher gamma-glutamyltransferase, lower albumin, decreased CD4+ T cells and B lymphocytes. Ultrastructural examination identified typical coronavirus particles, characterized by spike structures, in the cytoplasm of hepatocytes in 2 COVID-19 cases. SARS-CoV-2-infected hepatocytes displayed conspicuous mitochondrial swelling, endoplasmic reticulum dilatation and glycogen granule decrease. Histologically, massive hepatic apoptosis and some binuclear hepatocytes were observed. Taken together, both ultrastructural and histological evidence indicated a typical lesion of viral infection. Immunohistochemical results showed scarce CD4+ and CD8+ lymphocytes. No obvious eosinophil infiltration, cholestasis, fibrin deposition, granuloma, massive central necrosis, or interface hepatitis were observed. Conclusions SARS-CoV-2 infection in the liver directly contributes to hepatic impairment in patients with COVID-19. Hence, a surveillance of viral clearance in liver and long-term outcome of COVID-19 is required. Lay summary Liver enzyme abnormalities are common in patients with coronavirus disease 2019 (COVID-19). We reported the clinical characteristics and liver pathological manifestations of COVID-19 patients with elevated liver enzymes. Our findings suggested that SARS-CoV-2 infection of the liver is a crucial factor contributing to hepatic impairment in patients with COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884 · cited 1×
“Mechanistically, proinflammatory cytokines were reported to increase significantly in severe COVID-19 cases.(4,15) This event often provokes systemic ischemia and hypoxia, which is blamed for inadequate pulmonary ventilation, manifesting as an elevation of A-aDO2.”
Self-citationA novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Self-citationA pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Self-citationChen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Self-citationAngiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Self-citationHamming, I., Timens, W., Bulthuis, M., Lely, A., Navis, G., & van Goor, H. (2004) · The Journal of Pathology · doi:10.1002/path.1570 · Cited by 5,676
Clinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750
Self-citationA Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong
Lee, N., Hui, D., Wu, A., Chan, P., Cameron, P., Joynt, G. M., Ahuja, A., Yung, M. Y., Leung, C. B., To, K. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030685 · Cited by 2,628
Xu, X.-W., Wu, X.-X., Jiang, X.-G., Xu, K.-J., Ying, L.-J., Ma, C.-L., Li, S.-B., Wang, H.-Y., Zhang, S., Gao, H.-N., et al. (2020) · BMJ · doi:10.1136/bmj.m606 · Cited by 2,046
Self-citationIdentification of Severe Acute Respiratory Syndrome in Canada
Poutanen, S. M., Low, D. E., Henry, B., Finkelstein, S., Rose, D., Green, K., Tellier, R., Draker, R., Adachi, D., Ayers, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030634 · Cited by 1,132
A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong Kong
Tsang, K. W., Ho, P. L., Ooi, G. C., Yee, W. K., Wang, T., Chan-Yeung, M., Lam, W. K., Seto, W. H., Yam, L. Y., Cheung, T. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030666 · Cited by 1,017
SARS-associated viral hepatitis caused by a novel coronavirus: Report of three cases
Chau, T.-N., Lee, K.-C., Yao, H., Tsang, T.-Y., Chow, T.-C., Yeung, Y.-C., Choi, K.-W., Tso, Y.-K., Lau, T., Lai, S.-T., et al. (2004) · Hepatology · doi:10.1002/hep.20111 · Cited by 424
Ischemic hepatitis: clinical presentation and pathogenesis
Seeto, R. K., Fenn, B., & Rockey, D. C. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00461-7 · Cited by 360
Hypoxic Hepatitis: Clinical and Hemodynamic Study in 142 Consecutive Cases
Henrion, J., Schapira, M., Luwaert, R., Colin, L., Delannoy, A., & Heller, F. R. (2003) · Medicine · doi:10.1097/01.md.0000101573.54295.bd · Cited by 326
Chen, J., & Subbarao, K. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141706 · Cited by 251
Hepatic steatosis in chronic hepatitis B and C: Predictors, distribution and effect on fibrosis
Gordon, A., McLean, C., Pedersen, J. S., Bailey, M., & Roberts, S. K. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.01.031 · Cited by 152
Bessone, F., Dirchwolf, M., Rodil, M. A., Razori, M. V., & Roma, M. G. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14952 · Cited by 102
The spectrum of pathological changes in severe acute respiratory syndrome (SARS)
Cheung, O.-Y., Chan, J. W. M., Ng, C. K., & Koo, C. (2004) · Histopathology · doi:10.1111/j.1365-2559.2004.01926.x · Cited by 93
Sudden unexpected death of a 17-year-old male infected with the influenza virus
Nishida, N., Chiba, T., Ohtani, M., et al. (2004) · Legal Medicine · doi:10.1016/j.legalmed.2004.08.002 · Cited by 8
Cited by
Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19
Bonaventura, A., Vecchié, A., Dagna, L., Martinod, K., Dixon, D. L., Van Tassell, B. W., Dentali, F., Montecucco, F., Massberg, S., Levi, M., et al. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00536-9 · Cited by 987
Marjot, T., Moon, A. M., Cook, J. A., Abd-Elsalam, S., Aloman, C., Armstrong, M. J., Pose, E., Brenner, E. J., Cargill, T., Catana, M.-A., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.09.024 · Cited by 518
Long-term complications of COVID-19
Desai, A. D., Lavelle, M., Boursiquot, B. C., & Wan, E. Y. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00375.2021 · Cited by 415
Pathophysiological mechanisms of liver injury in COVID‐19
Nardo, A. D., Schneeweiss‐Gleixner, M., Bakail, M., Dixon, E. D., Lax, S. F., & Trauner, M. (2021) · Liver International · doi:10.1111/liv.14730 · Cited by 397
COVID-19 and liver disease: mechanistic and clinical perspectives
Marjot, T., Webb, G. J., Barritt, A. S., Moon, A. M., Stamataki, Z., Wong, V. W., & Barnes, E. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00426-4 · Cited by 385
Metadata
- Authors
- Wang, Y., Liu, S., Liu, H., Li, W., Lin, F., Jiang, L., Li, X., Xu, P., Zhang, L., Zhao, L., Cao, Y., Kang, J., Yang, J., Li, L., Liu, X., Li, Y., Nie, R., Mu, J., Lu, F., Zhao, S., Lu, J., & Zhao, J.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 73
- Issue
- 4
- Pages
- 807-816
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W3023986730
- Cited by
- 626
- References
- 19
- FWCI
- 16.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.